In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away Lausanne, Switzerland

Scientific Leader and Friend

Lausanne, Switzerland,

December 7, 2018 - AC Immune SA (NASDAQ: ACIU), announced today that its Chief Scientific Officer, Dr. Andreas Muhs,

passed away following a period of illness.

is with great sadness that we announce the passing of Dr. Andreas Muhs. Everyone at AC Immune will miss him more than words

can express and our thoughts go to Andreas' family and to those closest to him,"

said Prof. Andrea Pfeifer, CEO of

AC Immune. "With his great scientific insight, experience and commitment, Andreas

has been an outstanding leader and with his genuine interest in people, he became a mentor and friend to many of us at AC Immune."

AC Immune's research team will continue

to be led on an interim basis by Dr. David Lowe, who has been serving in this role since Dr. Muhs' leave of absence announced

by AC Immune in October 2018. Dr. Lowe has served as AC Immune's Deputy Chief Scientific Officer and more recently as Innovation

Fellow since January 2014. AC Immune's board of directors is meeting shortly regarding succession and will inform in due

AC Immune is a clinical-stage Swiss-based

biopharmaceutical company, listed on NASDAQ, which aims to become a global leader in precision medicine for neurodegenerative diseases.

The Company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases

caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines

designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's

pipeline features nine therapeutic and three diagnostic product candidates - with five product candidates currently in clinical

trials. The most advanced of these is crenezumab, a humanized anti-amyloid- monoclonal IgG4 antibody that targets monomeric

and aggregated forms of amyloid- , with highest affinity for neurotoxic oligomers. Crenezumab is currently in two Phase 3

clinical studies for AD, under a global program conducted by the collaboration partner Roche/Genentech. Other collaborations include

Biogen, Janssen Pharmaceuticals, Nestl Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging)

and Essex Bio-Technology.

Forward looking statements

This press release contains statements that

constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section

21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include

statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In

some cases, you can identify these statements by forward-looking words such as "may," "might," "will,"

"should," "expects," "plans," "anticipates," "believes," "estimates,"

"predicts," "projects," "potential," "outlook" or "continue," and other

comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve

significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from

those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3.

Key Information - Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's

Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only

as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future

developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their

entirety by this cautionary statement.

For further information, please contact: